Literature DB >> 31358978

The myth of 'stable' coronary artery disease.

Keith A A Fox1, Marco Metra2, João Morais3, Dan Atar4,5.   

Abstract

Patients with known cardiovascular disease who have not had a recent acute event are often referred to as having stable coronary artery disease (CAD). The concept of 'stable' CAD is misleading for two important reasons: the continuing risks of cardiovascular events over the longer term and the diverse spectrum of powerful risk characteristics. The risks of cardiovascular events are frequently underestimated and continue to exist, despite current standards of care for secondary prevention, including lifestyle changes, optimal medical therapy, myocardial revascularization and the use of antiplatelet agents to limit thrombosis. In dispelling the myth of 'stable' CAD, we explore the pathophysiology of the disease and the relative contribution of plaque and systemic factors to cardiovascular events. A broader concept of the vulnerable patient, not just the vulnerable plaque, takes into account the diversity and future risks of atherothrombotic events. We also evaluate new and ongoing research into medical therapies aimed at further reducing the risks of cardiovascular events in patients with chronic - but not stable - atherothrombotic disease.

Entities:  

Mesh:

Year:  2019        PMID: 31358978     DOI: 10.1038/s41569-019-0233-y

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN: 1759-5002            Impact factor:   32.419


  102 in total

1.  2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology.

Authors:  Gilles Montalescot; Udo Sechtem; Stephan Achenbach; Felicita Andreotti; Chris Arden; Andrzej Budaj; Raffaele Bugiardini; Filippo Crea; Thomas Cuisset; Carlo Di Mario; J Rafael Ferreira; Bernard J Gersh; Anselm K Gitt; Jean-Sebastien Hulot; Nikolaus Marx; Lionel H Opie; Matthias Pfisterer; Eva Prescott; Frank Ruschitzka; Manel Sabaté; Roxy Senior; David Paul Taggart; Ernst E van der Wall; Christiaan J M Vrints; Jose Luis Zamorano; Stephan Achenbach; Helmut Baumgartner; Jeroen J Bax; Héctor Bueno; Veronica Dean; Christi Deaton; Cetin Erol; Robert Fagard; Roberto Ferrari; David Hasdai; Arno W Hoes; Paulus Kirchhof; Juhani Knuuti; Philippe Kolh; Patrizio Lancellotti; Ales Linhart; Petros Nihoyannopoulos; Massimo F Piepoli; Piotr Ponikowski; Per Anton Sirnes; Juan Luis Tamargo; Michal Tendera; Adam Torbicki; William Wijns; Stephan Windecker; Juhani Knuuti; Marco Valgimigli; Héctor Bueno; Marc J Claeys; Norbert Donner-Banzhoff; Cetin Erol; Herbert Frank; Christian Funck-Brentano; Oliver Gaemperli; José R Gonzalez-Juanatey; Michalis Hamilos; David Hasdai; Steen Husted; Stefan K James; Kari Kervinen; Philippe Kolh; Steen Dalby Kristensen; Patrizio Lancellotti; Aldo Pietro Maggioni; Massimo F Piepoli; Axel R Pries; Francesco Romeo; Lars Rydén; Maarten L Simoons; Per Anton Sirnes; Ph Gabriel Steg; Adam Timmis; William Wijns; Stephan Windecker; Aylin Yildirir; Jose Luis Zamorano
Journal:  Eur Heart J       Date:  2013-08-30       Impact factor: 29.983

2.  Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.

Authors:  Christopher P Cannon; Michael A Blazing; Robert P Giugliano; Amy McCagg; Jennifer A White; Pierre Theroux; Harald Darius; Basil S Lewis; Ton Oude Ophuis; J Wouter Jukema; Gaetano M De Ferrari; Witold Ruzyllo; Paul De Lucca; KyungAh Im; Erin A Bohula; Craig Reist; Stephen D Wiviott; Andrew M Tershakovec; Thomas A Musliner; Eugene Braunwald; Robert M Califf
Journal:  N Engl J Med       Date:  2015-06-03       Impact factor: 91.245

3.  Vorapaxar in the secondary prevention of atherothrombotic events.

Authors:  David A Morrow; Eugene Braunwald; Marc P Bonaca; Sebastian F Ameriso; Anthony J Dalby; Mary Polly Fish; Keith A A Fox; Leslie J Lipka; Xuan Liu; José Carlos Nicolau; A J Oude Ophuis; Ernesto Paolasso; Benjamin M Scirica; Jindrich Spinar; Pierre Theroux; Stephen D Wiviott; John Strony; Sabina A Murphy
Journal:  N Engl J Med       Date:  2012-03-24       Impact factor: 91.245

4.  Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.

Authors:  Stuart J Connolly; John W Eikelboom; Jackie Bosch; Gilles Dagenais; Leanne Dyal; Fernando Lanas; Kaj Metsarinne; Martin O'Donnell; Anthony L Dans; Jong-Won Ha; Alexandr N Parkhomenko; Alvaro A Avezum; Eva Lonn; Liu Lisheng; Christian Torp-Pedersen; Petr Widimsky; Aldo P Maggioni; Camilo Felix; Katalin Keltai; Masatsugu Hori; Khalid Yusoff; Tomasz J Guzik; Deepak L Bhatt; Kelley R H Branch; Nancy Cook Bruns; Scott D Berkowitz; Sonia S Anand; John D Varigos; Keith A A Fox; Salim Yusuf
Journal:  Lancet       Date:  2017-11-10       Impact factor: 79.321

5.  Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.

Authors:  Paul M Ridker; Brendan M Everett; Tom Thuren; Jean G MacFadyen; William H Chang; Christie Ballantyne; Francisco Fonseca; Jose Nicolau; Wolfgang Koenig; Stefan D Anker; John J P Kastelein; Jan H Cornel; Prem Pais; Daniel Pella; Jacques Genest; Renata Cifkova; Alberto Lorenzatti; Tamas Forster; Zhanna Kobalava; Luminita Vida-Simiti; Marcus Flather; Hiroaki Shimokawa; Hisao Ogawa; Mikael Dellborg; Paulo R F Rossi; Roland P T Troquay; Peter Libby; Robert J Glynn
Journal:  N Engl J Med       Date:  2017-08-27       Impact factor: 91.245

6.  Risk score for predicting death, myocardial infarction, and stroke in patients with stable angina, based on a large randomised trial cohort of patients.

Authors:  Tim C Clayton; Jacobus Lubsen; Stuart J Pocock; Zoltán Vokó; Bridget-Anne Kirwan; Keith A A Fox; Philip A Poole-Wilson
Journal:  BMJ       Date:  2005-10-06

Review 7.  Pathophysiology of coronary artery disease.

Authors:  Peter Libby; Pierre Theroux
Journal:  Circulation       Date:  2005-06-28       Impact factor: 29.690

8.  Long-term use of ticagrelor in patients with prior myocardial infarction.

Authors:  Marc P Bonaca; Deepak L Bhatt; Marc Cohen; Philippe Gabriel Steg; Robert F Storey; Eva C Jensen; Giulia Magnani; Sameer Bansilal; M Polly Fish; Kyungah Im; Olof Bengtsson; Ton Oude Ophuis; Andrzej Budaj; Pierre Theroux; Mikhail Ruda; Christian Hamm; Shinya Goto; Jindrich Spinar; José Carlos Nicolau; Robert G Kiss; Sabina A Murphy; Stephen D Wiviott; Peter Held; Eugene Braunwald; Marc S Sabatine
Journal:  N Engl J Med       Date:  2015-03-14       Impact factor: 91.245

Review 9.  The myth of the "vulnerable plaque": transitioning from a focus on individual lesions to atherosclerotic disease burden for coronary artery disease risk assessment.

Authors:  Armin Arbab-Zadeh; Valentin Fuster
Journal:  J Am Coll Cardiol       Date:  2015-01-16       Impact factor: 24.094

Review 10.  Update on acute coronary syndromes: the pathologists' view.

Authors:  Erling Falk; Masataka Nakano; Jacob Fog Bentzon; Aloke V Finn; Renu Virmani
Journal:  Eur Heart J       Date:  2012-12-13       Impact factor: 29.983

View more
  22 in total

1.  State of Knowledge on Molecular Adaptations to Exercise in Humans: Historical Perspectives and Future Directions.

Authors:  Kaleen M Lavin; Paul M Coen; Liliana C Baptista; Margaret B Bell; Devin Drummer; Sara A Harper; Manoel E Lixandrão; Jeremy S McAdam; Samia M O'Bryan; Sofhia Ramos; Lisa M Roberts; Rick B Vega; Bret H Goodpaster; Marcas M Bamman; Thomas W Buford
Journal:  Compr Physiol       Date:  2022-03-09       Impact factor: 8.915

2.  The effect of LDL-C status on the association between increased coronary artery calcium score and compositional plaque volume progression in statins-treated diabetic patients: evaluated using serial coronary CTAs.

Authors:  Yuan Li; Zhi-Gang Yang; Rui Shi; Yue Gao; Li-Ling Shen; Ke Shi; Jin Wang; Li Jiang
Journal:  Cardiovasc Diabetol       Date:  2022-06-30       Impact factor: 8.949

3.  A Coronary Artery Disease Monitoring Model Built from Clinical Data and Alpha-1-Antichymotrypsin.

Authors:  Chen-Chi Chang; I-Jung Tsai; Wen-Chi Shen; Hung-Yi Chen; Po-Wen Hsu; Ching-Yu Lin
Journal:  Diagnostics (Basel)       Date:  2022-06-08

Review 4.  Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease.

Authors:  Davide Capodanno; Deepak L Bhatt; John W Eikelboom; Keith A A Fox; Tobias Geisler; C Michael Gibson; Jose Ramon Gonzalez-Juanatey; Stefan James; Renato D Lopes; Roxana Mehran; Gilles Montalescot; Manesh Patel; P Gabriel Steg; Robert F Storey; Pascal Vranckx; Jeffrey I Weitz; Robert Welsh; Uwe Zeymer; Dominick J Angiolillo
Journal:  Nat Rev Cardiol       Date:  2020-01-17       Impact factor: 32.419

5.  Optimising Secondary Prevention and Cardiac Rehabilitation for Atherosclerotic Cardiovascular Disease During the COVID-19 Pandemic: A Position Statement From the Cardiac Society of Australia and New Zealand (CSANZ).

Authors:  Stephen J Nicholls; Mark Nelson; Carolyn Astley; Tom Briffa; Alex Brown; Robyn Clark; David Colquhoun; Robyn Gallagher; David L Hare; Sally Inglis; Michael Jelinek; Adrienne O'Neil; Rosy Tirimacco; Margarite Vale; Julie Redfern
Journal:  Heart Lung Circ       Date:  2020-04-30       Impact factor: 2.975

6.  Bioinformatics analysis identifies potential diagnostic signatures for coronary artery disease.

Authors:  Dong Zhang; Liying Guan; Xiaoming Li
Journal:  J Int Med Res       Date:  2020-12       Impact factor: 1.671

7.  Metabolic Syndrome and Coronary Artery Disease Risk: A Meta-Analysis of Observational Studies.

Authors:  Amal F Alshammary; Khalid Khalaf Alharbi; Naif Jameel Alshehri; Vishal Vennu; Imran Ali Khan
Journal:  Int J Environ Res Public Health       Date:  2021-02-11       Impact factor: 3.390

Review 8.  Coronary Revascularization and Long-Term Survivorship in Chronic Coronary Syndrome.

Authors:  Ana Gabaldon-Perez; Victor Marcos-Garces; Jose Gavara; Cesar Rios-Navarro; Gema Miñana; Antoni Bayes-Genis; Oliver Husser; Juan Sanchis; Julio Nunez; Francisco Javier Chorro; Vicente Bodi
Journal:  J Clin Med       Date:  2021-02-05       Impact factor: 4.241

Review 9.  A pathophysiological compass to personalize antianginal drug treatment.

Authors:  Edoardo Bertero; Gerd Heusch; Thomas Münzel; Christoph Maack
Journal:  Nat Rev Cardiol       Date:  2021-07-07       Impact factor: 32.419

10.  Cost-Effectiveness of Coronary and Peripheral Artery Disease Antithrombotic Treatments in Finland.

Authors:  Erkki Soini; Outi Virtanen; Saku Väätäinen; Jean-Baptiste Briere; Kevin Bowrin; Aurelie Millier
Journal:  Adv Ther       Date:  2020-06-09       Impact factor: 3.845

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.